Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
Clearside Biomedical, Inc. entered into Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co. valued at $50 million (effective 2023-05-12).
- Action
- entry
- Agreement
- atm program
- Counterparty
- Cantor Fitzgerald & Co.
- Value
- $50 million
- Effective
- 2023-05-12
Exact text from the filing
On May 12, 2023, Clearside Biomedical, Inc. (the “ Company ”) entered into a Controlled Equity Offering SM Sales Agreement (the “ Agreement ”) with Cantor Fitzgerald & Co. (“ Cantor ”) under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.001 per share (the “ Common Stock ”), having an aggregate offering price of up to $50 million through or to Cantor as its sales agent or principal.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
Clearside Biomedical, Inc. terminated Sales Agreement dated June 30, 2017 with Cowen and Company, LLC with Cowen and Company, LLC valued at terminated (effective 2023-05-12).
- Action
- termination
- Agreement
- atm program
- Counterparty
- Cowen and Company, LLC
- Value
- terminated
- Effective
- 2023-05-12
Exact text from the filing
On May 12, 2023, the Company and Cowen and Company, LLC (“ Cowen ”) agreed to terminate the Sales Agreement, dated as of June 30, 2017, (the “ Prior Sales Agreement ”) between the Company and Cowen, effective as of May 12, 2023 (the “ Termination Date ”).
View on SEC.gov